Novartis warns US plan to curb drug prices could hit key research
The US President Joe Biden in August signed into law the Inflation Reduction Act (IRA), which allows the federal Medicare scheme…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Novartis
Dr Reddy’s reduces price of cardiovascular drug Cidmus
Following price reduction, Cidmus will be priced at Rs 29 for 50 mg, Rs 49 for 100 mg and Rs
79 for 200 mg per tablet
EMA seeks to issue guidance on liver damage from Novartis’s gene therapy
The statement follows recent deaths due to liver failure after treatment with the gene therapy, the EMA said
Novartis to uphold generic drug supply despite surging energy costs
The generic drugmakers’ association in Europe last month warned that production of some medicines may have to be stopped because…
US Supreme Court rebuffs Novartis, allows generic versions of MS drug
Novartis had asked the justices to suspend a lower court's ruling that lifted a ban on generic versions of Gilenya, the…
Novartis drug shown to ease symptoms of painful skin condition
The drug, already approved for conditions like psoriasis and arthritis, demonstrated rapid and sustained relief in trial…
Novartis to spin off generics business Sandoz next year
The company started a strategic review of Sandoz last October - examining a range of options, including retaining the business,…
Novartis fails again to reuse anti-inflammatory drug to treat lung cancer
The failure in the latest trial, called Canopy A, is a setback for Novartis after canakinumab failed in two separate studies last…
Novartis’s tislelizumab phase-III trial data shows survival results in esophageal cancer
First-line tislelizumab plus chemotherapy showed median Overall Survival (OS) of 17.2 months versus 10.6 months for chemotherapy…
EMA recommends marketing authorisation for Scemblix by Novartis
While many patients will benefit from available TKI therapies, a significant proportion may experience intolerance or resistance…